Hepatoma-derived growth factor (HDGF) is a secreted protein initially identified in hepatocellular carcinoma cells. It belongs to the HDGF-related protein (HRP) family, characterized by a conserved N-terminal PWWP domain involved in chromatin interactions and nuclear localization. HDGF plays multifunctional roles in cell proliferation, angiogenesis, apoptosis, and tissue repair by regulating gene expression and signaling pathways. Its overexpression correlates with poor prognosis in various cancers, including liver, lung, breast, and gastrointestinal malignancies, making it a potential therapeutic target.
HDGF antibodies are essential tools for detecting HDGF expression and studying its biological functions. They enable researchers to visualize HDGF localization (nuclear or cytoplasmic) via immunohistochemistry (IHC) or immunofluorescence (IF), quantify protein levels using Western blot (WB) or ELISA, and investigate protein-protein interactions through immunoprecipitation (IP). Both polyclonal and monoclonal antibodies are available, often targeting specific regions like the N-terminal domain. Validation includes testing specificity using HDGF-knockout controls and confirming cross-reactivity across species (human, mouse, rat).
These antibodies have advanced cancer research by elucidating HDGF's role in tumor progression, metastasis, and drug resistance. Emerging studies also explore HDGF's involvement in non-cancer pathologies, such as cardiovascular diseases and pulmonary fibrosis. However, challenges remain in standardizing antibody performance across experimental conditions and ensuring consistent reproducibility in clinical applications.